written on 27.06.2014

BMS's daclatasvir is first in class to garner CHMP nod


Daclatasvir is part of a fairly crowded and impressive field of new direct acting antivirals in the hepatitis C arena, which have rapidly transformed the outlook for infected patients and herald an age when the old interferon-based regimens may become…